Related Experiment Video
Updated: May 24, 2026
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Langerhans cell histiocytosis
Ligaya Park1, Clayton Schiltz, Neil Korman
1Department of Dermatology, Case Medical Center, Cleveland, OH, USA. ligaya.park@uhhospitals.org
Insights
Cutaneous Langerhans cell histiocytosis (LCH) is rare and variable, delaying diagnosis. Skin biopsies confirm LCH, with treatment often starting with steroids, adjusting based on response.
Area of Science:
- Dermatology
- Pediatric Pathology
- Oncology
Background:
- Cutaneous Langerhans cell histiocytosis (LCH) is an uncommon condition with diverse presentations.
- Variability in skin manifestations can impede timely diagnosis.
Observation:
- This study reviews a case of cutaneous LCH and relevant literature.
- Diagnostic criteria include skin biopsies positive for CD1a and/or langerin.
Findings:
- Evaluation involves a comprehensive review of systems, laboratory tests, and imaging to assess LCH extent.
- Initial treatment for cutaneous LCH typically involves topical or oral steroids.
- Treatment response assessment at six weeks guides therapy intensification for systemic disease.
Implications:
- Lack of specific LCH treatment guidelines necessitates reliance on Histiocyte Society recommendations.
- Standardized diagnostic and treatment approaches are crucial for improving patient outcomes in rare LCH cases.
Background:
The cutaneous presentation of Langerhans cell histiocytosis (LCH) is very rare and can be highly variable among individuals, which can often lead to a delay in diagnosis.
Objective:
To discuss a case report and literature review of important clinical indicators, histology, diagnosis, evaluation, and treatment guidelines.
Methods:
Case report and literature review.
Results:
Skin biopsies positive for CD1a and/or langerin are diagnostic for LCH. A thorough review of systems, baseline laboratory tests, and imaging studies can determine the extent of LCH. Treatment of cutaneous disease is largely based on case report and small case studies, but baseline treatment should generally begin with oral or topical steroids. When patients have more severe disease that requires a systemic approach, the efficacy of therapy should be assessed 6 weeks into therapy, with subsequent treatment intensification in patients with limited response.
Conclusion:
Owing to the rarity of this condition, there are no specific guidelines for treatment of LCH, but guidelines put forth by the Histiocyte Society assist in categorization and basic treatment approaches for patients with systemic disease.
